| Literature DB >> 35791027 |
Karl H Hillebrandt1,2, Simon Moosburner3,4, Axel Winter1, Nora Nevermann1, Nathanael Raschzok1, Thomas Malinka1, Igor M Sauer1, Moritz Schmelzle1, Johann Pratschke1, Sascha Chopra1.
Abstract
BACKGROUND: Due to the COVID-19 pandemic, an extensive reorganisation of healthcare resources was necessary-with a particular impact on surgical care across all disciplines. However, the direct and indirect consequences of this redistribution of resources on surgical therapy and care are largely unknown.Entities:
Keywords: COVID-19 pandemic; Quality management; Surgery
Mesh:
Year: 2022 PMID: 35791027 PMCID: PMC9253238 DOI: 10.1186/s12893-022-01708-7
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.030
Fig. 1Patient flow chart, inclusion and exclusion criteria. Patients were stratified after year of surgical treatment (2018, 2019 and 2020) as well as the corresponding time periods of COVID-19 prevalence peaks (March–May and October–December of 2020)
Fig. 2SARS-CoV-2 Infections in Germany 2020. Daily rate of new infections as reported by the Robert-Koch-Institute. Periods of high COVID-19 burden (COVID-19 Period; COVID-19) from March to May and October to end of December 2020 are highlighted in red. Number of patients surgically treated at our centre in blue, patients receiving conservative treatment in green
Fig. 3Physical status according to the ASA-Score and complications classified after Clavien-Dindo. Patients are stratified after analysis year as well as periods of high COVID-19 burden (COVID-19) from March to May and October to end of December 2020 compared to the corresponding reference (REF) period in 2018 and 2019. A, B ASA-Score. C, D Complications
Descriptive patient data
| Variable | Year | COVID-19 period | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall, | 2018, | 2019, | 2020, | p-valueb | q-valuec | Overall, N = 4510a | 2018 Reference, N = 1631a | 2019 Reference, N = 1658a | COVID-19, | p-valueb | q-valuec | |
| Sex (f) | 4744 (44%) | 1517 (43%) | 1688 (45%) | 1539 (45%) | 0.2 | 0.3 | 1990 (44%) | 705 (43%) | 749 (45%) | 536 (44%) | 0.5 | 0.6 |
| Age in years | 52 (38, 63) | 53 (39, 64) | 52 (37, 63) | 52 (38, 63) | 0.068 | 0.11 | 52 (38, 63) | 52 (38, 64) | 52 (37, 63) | 54 (40, 64) | 0.038 | 0.10 |
| Campus | < 0.001 | 0.002 | 0.5 | 0.5 | ||||||||
| Charite Mitte | 4166 (39%) | 1459 (41%) | 1407 (37%) | 1300 (38%) | 1671 (37%) | 621 (38%) | 612 (37%) | 438 (36%) | ||||
| Charite Virchow-Klinikum | 6557 (61%) | 2062 (59%) | 2369 (63%) | 2126 (62%) | 2839 (63%) | 1.10 (62%) | 1.46 (63%) | 783 (64%) | ||||
| Length of hospital stay | 7 (5, 13) | 8 (5, 14) | 7 (5, 12) | 7 (5, 13) | < 0.001 | 0.001 | 8 (5, 14) | 8 (5, 13) | 7 (5, 13) | 8 (5, 15) | 0.002 | 0.013 |
| Indication for surgery | < 0.001 | < 0.001 | < 0.001 | < 0.001 | ||||||||
| Appendix | 542 (5.1%) | 135 (3.8%) | 213 (5.6%) | 194 (5.7%) | 231 (5.1%) | 77 (4.7%) | 88 (5.3%) | 66 (5.4%) | ||||
| Colorectal | 1,715 (16%) | 513 (15%) | 608 (16%) | 594 (17%) | 753 (17%) | 239 (15%) | 278 (17%) | 236 (19%) | ||||
| Gallbladder | 485 (4.5%) | 133 (3.8%) | 192 (5.1%) | 160 (4.7%) | 213 (4.7%) | 82 (5.0%) | 83 (5.0%) | 48 (3.9%) | ||||
| Hepatobiliary | 916 (8.5%) | 317 (9.0%) | 318 (8.4%) | 281 (8.2%) | 407 (9.0%) | 149 (9.1%) | 144 (8.7%) | 114 (9.3%) | ||||
| Hernia | 963 (9.0%) | 339 (9.6%) | 368 (9.7%) | 256 (7.5%) | 387 (8.6%) | 152 (9.3%) | 167 (10%) | 68 (5.6%) | ||||
| Others | 1,111 (10%) | 352 (10.0%) | 414 (11%) | 345 (10%) | 414 (9.2%) | 144 (8.8%) | 163 (9.8%) | 107 (8.8%) | ||||
| Pancreas | 554 (5.2%) | 179 (5.1%) | 200 (5.3%) | 175 (5.1%) | 216 (4.8%) | 74 (4.5%) | 80 (4.8%) | 62 (5.1%) | ||||
| Parathyroid | 213 (2.0%) | 63 (1.8%) | 86 (2.3%) | 64 (1.9%) | 82 (1.8%) | 30 (1.8%) | 32 (1.9%) | 20 (1.6%) | ||||
| Peritoneal malignancies | 192 (1.8%) | 74 (2.1%) | 62 (1.6%) | 56 (1.6%) | 75 (1.7%) | 34 (2.1%) | 23 (1.4%) | 18 (1.5%) | ||||
| Small intestine | 408 (3.8%) | 140 (4.0%) | 122 (3.2%) | 146 (4.3%) | 182 (4.0%) | 67 (4.1%) | 60 (3.6%) | 55 (4.5%) | ||||
| Thorax | 1,362 (13%) | 455 (13%) | 438 (12%) | 469 (14%) | 576 (13%) | 218 (13%) | 185 (11%) | 173 (14%) | ||||
| Thyroid | 536 (5.0%) | 152 (4.3%) | 194 (5.1%) | 190 (5.5%) | 214 (4.7%) | 59 (3.6%) | 91 (5.5%) | 64 (5.2%) | ||||
| Transplantation | 466 (4.3%) | 152 (4.3%) | 148 (3.9%) | 166 (4.8%) | 193 (4.3%) | 61 (3.7%) | 72 (4.3%) | 60 (4.9%) | ||||
| Upper GI | 842 (7.9%) | 240 (6.8%) | 295 (7.8%) | 307 (9.0%) | 389 (8.6%) | 114 (7.0%) | 152 (9.2%) | 123 (10%) | ||||
| Vascular | 418 (3.9%) | 277 (7.9%) | 118 (3.1%) | 23 (0.7%) | 178 (3.9%) | 131 (8.0%) | 40 (2.4%) | 7 (0.6%) | ||||
| Postoperative complications | < 0.001 | 0.002 | 0.2 | 0.3 | ||||||||
| No complications | 8450 (79%) | 2,725 (77%) | 3001 (79%) | 2724 (80%) | 3535 (78%) | 1280 (78%) | 1309 (79%) | 946 (77%) | ||||
| Clavien-Dindo I | 385 (3.6%) | 123 (3.5%) | 158 (4.2%) | 104 (3.0%) | 165 (3.7%) | 53 (3.2%) | 69 (4.2%) | 43 (3.5%) | ||||
| Clavien-Dindo II | 463 (4.3%) | 171 (4.9%) | 162 (4.3%) | 130 (3.8%) | 186 (4.1%) | 71 (4.4%) | 64 (3.9%) | 51 (4.2%) | ||||
| Clavien-Dindo IIIa | 438 (4.1%) | 139 (3.9%) | 148 (3.9%) | 151 (4.4%) | 182 (4.0%) | 54 (3.3%) | 73 (4.4%) | 55 (4.5%) | ||||
| Clavien-Dindo IIIb | 509 (4.7%) | 195 (5.5%) | 158 (4.2%) | 156 (4.6%) | 212 (4.7%) | 89 (5.5%) | 69 (4.2%) | 54 (4.4%) | ||||
| Clavien-Dindo IVa | 266 (2.5%) | 75 (2.1%) | 96 (2.5%) | 95 (2.8%) | 122 (2.7%) | 41 (2.5%) | 45 (2.7%) | 36 (2.9%) | ||||
| Clavien-Dindo IVb | 69 (0.6%) | 32 (0.9%) | 18 (0.5%) | 19 (0.6%) | 34 (0.8%) | 14 (0.9%) | 13 (0.8%) | 7 (0.6%) | ||||
| Clavien-Dindo V | 143 (1.3%) | 61 (1.7%) | 35 (0.9%) | 47 (1.4%) | 74 (1.6%) | 29 (1.8%) | 16 (1.0%) | 29 (2.4%) | ||||
| ASA | < 0.001 | 0.002 | < 0.001 | 0.006 | ||||||||
| ASA 1 | 898 (9.5%) | 207 (7.9%) | 327 (9.2%) | 364 (11%) | 401 (10%) | 112 (9.2%) | 155 (10%) | 134 (12%) | ||||
| ASA 2 | 4184 (44%) | 1220 (47%) | 1643 (46%) | 1321 (41%) | 1,717 (44%) | 572 (47%) | 702 (45%) | 443 (38%) | ||||
| ASA 3 | 4064 (43%) | 1146 (44%) | 1470 (41%) | 1448 (45%) | 1,691 (43%) | 513 (42%) | 642 (41%) | 536 (46%) | ||||
| ASA 4 | 261 (2.8%) | 50 (1.9%) | 104 (2.9%) | 107 (3.3%) | 111 (2.8%) | 24 (2.0%) | 47 (3.0%) | 40 (3.5%) | ||||
| ASA 5 | 9 (< 0.1%) | 0 (0%) | 7 (0.2%) | 2 (< 0.1%) | 5 (0.1%) | 0 (0%) | 3 (0.2%) | 2 (0.2%) | ||||
| Type of surgery | 0.006 | 0.016 | 0.5 | 0.5 | ||||||||
| Minor resection | 7250 (68%) | 2452 (70%) | 2505 (66%) | 2293 (67%) | 3031 (67%) | 1114 (68%) | 1107 (67%) | 810 (66%) | ||||
| Major resection | 3473 (32%) | 1069 (30%) | 1271 (34%) | 1133 (33%) | 1479 (33%) | 517 (32%) | 551 (33%) | 411 (34%) | ||||
| Complication | ||||||||||||
| Bleeding | 294 (2.7%) | 102 (2.9%) | 93 (2.5%) | 99 (2.9%) | 0.4 | 0.5 | 117 (2.6%) | 41 (2.5%) | 33 (2.0%) | 43 (3.5%) | 0.037 | 0.10 |
| Gastrointestinal | 543 (5.1%) | 180 (5.1%) | 181 (4.8%) | 182 (5.3%) | 0.6 | 0.7 | 234 (5.2%) | 74 (4.5%) | 82 (4.9%) | 78 (6.4%) | 0.075 | 0.2 |
| Cardiovascular | 207 (1.9%) | 82 (2.3%) | 63 (1.7%) | 62 (1.8%) | 0.10 | 0.2 | 95 (2.1%) | 37 (2.3%) | 28 (1.7%) | 30 (2.5%) | 0.3 | 0.5 |
| Hepatobiliary | 216 (2.0%) | 74 (2.1%) | 78 (2.1%) | 64 (1.9%) | 0.8 | 0.8 | 96 (2.1%) | 27 (1.7%) | 39 (2.4%) | 30 (2.5%) | 0.2 | 0.4 |
| Organisational | 384 (3.6%) | 231 (6.6%) | 87 (2.3%) | 66 (1.9%) | < 0.001 | < 0.001 | 189 (4.2%) | 116 (7.1%) | 34 (2.1%) | 39 (3.2%) | < 0.001 | < 0.001 |
| Pancreatic | 130 (1.2%) | 42 (1.2%) | 53 (1.4%) | 35 (1.0%) | 0.3 | 0.4 | 63 (1.4%) | 19 (1.2%) | 28 (1.7%) | 16 (1.3%) | 0.4 | 0.5 |
| Pulmonary | 741 (6.9%) | 269 (7.6%) | 235 (6.2%) | 237 (6.9%) | 0.058 | 0.11 | 336 (7.5%) | 124 (7.6%) | 112 (6.8%) | 100 (8.2%) | 0.3 | 0.5 |
| Renal | 453 (4.2%) | 174 (4.9%) | 157 (4.2%) | 122 (3.6%) | 0.016 | 0.036 | 199 (4.4%) | 74 (4.5%) | 69 (4.2%) | 56 (4.6%) | 0.8 | 0.8 |
| Infectious | 281 (2.6%) | 120 (3.4%) | 77 (2.0%) | 84 (2.5%) | < 0.001 | 0.003 | 123 (2.7%) | 47 (2.9%) | 36 (2.2%) | 40 (3.3%) | 0.2 | 0.3 |
| Transplantation | 142 (1.3%) | 44 (1.2%) | 38 (1.0%) | 60 (1.8%) | 0.020 | 0.039 | 60 (1.3%) | 16 (1.0%) | 18 (1.1%) | 26 (2.1%) | 0.016 | 0.074 |
| Surgical site infection | 604 (5.6%) | 196 (5.6%) | 207 (5.5%) | 201 (5.9%) | 0.8 | 0.8 | 253 (5.6%) | 75 (4.6%) | 93 (5.6%) | 85 (7.0%) | 0.025 | 0.091 |
LOS length of hospital stay, GI gastrointestinal, ASA American Society of Anesthesiologists, SSI surgical site infection
an (%); Median (IQR)
bPearson's Chi-squared test; Kruskal–Wallis rank sum test
cFalse discovery rate correction for multiple testing
Fig. 4Patient demographics stratified after analysis year as well as periods of high COVID-19 burden (COVID-19) from March to May and October to end of December 2020 compared to the corresponding reference (REF) period in 2018 and 2019. A, B Length of hospital stay in days 2019. B–D Patient age in years